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Background. Pancreatic enzyme supplementation is widely used to treat pain in patients with chronic pancreatitis, despite little
evidence for efficacy. We performed a systematic review of the literature and a meta-analysis to investigate its effectiveness.
Methods. All randomized controlled parallel or crossover trials in patients with chronic pancreatitis comparing pancreatic
enzyme supplementation to placebo were included. The main outcome was improvement in pain score or reduced analgesic
consumption. Two independent reviewers extracted data. Mantel-Haenszel random effect model meta-analysis was used whenever
methodologically appropriate. Results. Five out of 434 retrieved studies were included in the systematic review. All studies
used relatively similar methodology. Four studies using enteric-coated pancreatic enzyme supplementation failed to show any
improvement in pain as compared to placebo. The only study using non-enteric-coated enzymes did show reduction in the
pain score. There was significant heterogeneity among studies in both analyses. Random model meta-analysis of three studies
showed no significant difference in the mean of daily pain score (mean difference: 0.09 (1.57–1.39), 𝑝 = 0.91) or average weekly
analgesic consumption (mean difference: −0.30 (−2.37–1.77), 𝑝 = 0.77) between the periods of administering pancreatic enzyme
supplementation versus placebo. Conclusion. Pancreatic enzyme supplements do not seem to relieve abdominal pain in patients
with chronic pancreatitis and should not be prescribed solely for this purpose, given their significant cost and potential side effects.
1. Introduction
Abdominal pain is amajor complaint and difficult tomanage,
in patients with chronic pancreatitis [1]. Pancreatic enzyme
supplementation (PES) has been used extensively despite lack
of strong evidence for its efficacy, and the medications are
expensive.
The rationale for using PES is simple and logical. It
should inhibit the release of cholecystokinin and secretin
and thereby decrease the secretion and potential premature
activation of pancreatic enzymes in the pancreatic ducts,
which is believed to contribute to pancreatic pain [2].
However, this theory has not been proven. There have
been a few clinical trials (with significant heterogeneity in
their results), but, to our knowledge, there have been no
large randomized clinical trials or meta-analyses. Therefore,
we performed a systematic review of the literature and a
meta-analysis of relevant published randomized clinical trials
comparing PES with placebo in treating abdominal pain in
patients with chronic pancreatitis.
2. Material and Methods
2.1. Sources. Two independent reviewers performed
the search, risk of bias assessment, and data extraction
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(Mohammad Yaghoobi and Julia McNabb-Baltar). A third
reviewer (RB or Peter B. Cotton) was involved when a
consensus could not be achieved. Electronic searches were
conducted using OVID MEDLINE (1946 to January 2015),
EMBASE (1980 to January 2015), Cochrane library, and
ISI Web of knowledge from 1980 to January 2015. Articles
were selected using a highly sensitive search strategy, with
a combination of MeSH headings and text words that
included (i) chronic pancreatitis, (ii) enzymes, and (iii) pain.
Recursive searches and cross-referencing were carried out
using “similar articles” function. Bibliography of the articles
identified after an initial search was also manually reviewed.
The search was not restricted to any specific language
(Figures 2 and 3).
2.2. Study Selection. Randomized controlled parallel or
crossover trials were included. Included patients were those
with chronic pancreatitis. The intervention was pancre-
atic enzyme supplementation and the control was identical
placebo. The outcome of interest was improvement in pain
score or reduction in analgesic consumption.
Studies with missed or nonextractable data, studies in
children, abstracts, and duplicate publications were excluded.
No restrictions were applied in terms of language, geograph-
ical location, or quality of studies.
2.3. Heterogeneity. Variation in the patient populations and
the quality of studies was considered as a priori source of
heterogeneity. Subgroup analyses were predicted a priori to
investigate each source; however, no subgroup analysis could
be performed due to insufficient data.
2.4. Quality Assessment. Two reviewers retrieved the data.
The methodological quality of studies was assessed by using
Cochrane Collaboration tool for assessing the risk of bias [3].
No studies were excluded based on the quality score.
2.5. Statistical Analysis. Whenever at least two studies used
similar method in reporting the outcome, we planned to
performmeta-analysis of using theMantel-Haenszel method
and Review Manager 5.0.25. The random effects model was
applied since significant heterogeneity was predicted. A 𝑝
value of less than 0.05 was used as criterion for statistical
significance. 𝐼2 was generated to assess heterogeneity andwas
interpreted as previously described [4]. Test of heterogeneity
was considered significant if the 𝑝 value was less than 0.10.
All results are reported with 95% confidence intervals (CI)
when applicable. Sensitivity analyses were planned based on
the weight of the trials and by excluding each individual trial
in turn as recommended by Cochrane Collaboration open
learning material for reviewers [5].
3. Results
Five out of 434 retrieved studies were eligible and were
included in the systematic review. Figure 1 depicts the
PRISMA flow diagram. Table 1 depicts the characteristics of
included studies. Four studies were designed as crossover
438 records identified
through database
searching
8 additional records
identified through
other sources
434 records after duplicates removed
assessed for eligibility
44 of full-text articles 39 full-text
articles excluded
qualitative synthesis
5 studies included in
3 studies included in
quantitative synthesis
(meta-analysis)
Figure 1: The PRISMA flow diagram of study selection process.
double-blind randomized controlled trials and one as a par-
allel double-blind randomized controlled trial. Four studies
used enteric-coated enzymes and one non-enteric-coated
ones [7]. One study included eight postsurgical patients [7].
All studies used relatively similar methodology but reported
different outcomes. Only two studies used a similar scale
to report mean pain scores and therefore a meta-analysis
was done on these two studies [6, 8]. Moreover, two studies
reported average analgesic consumption similarly, thus being
appropriate to be included in a meta-analysis [7, 8].
3.1. Pain Alleviation. Four studies using enteric-coated pan-
creatic enzyme supplementation failed to show any improve-
ment in pain as compared to placebo.
The only study which showed improvement in pain score
was the oldest study and the only one using non-enteric-
coated enzymes [7]. This randomized crossover Swedish
study involved 19 patients with chronic pancreatitis (based
on the low pancreatic isoamylase in serum, abnormal Lundh
test, calcifications on plain X-ray, endoscopic retrograde
cholangiopancreatography (ERCP) findings, or operative and
histological findings), including eight who previously under-
went Puestow or duVal pancreatojejunostomy or subtotal
pancreatectomy. They randomly received one-week enzyme
supplementation or placebo preceded by a wash-out period
of one week. At the end of the study, 10 had responded
significantly to enzyme supplementation as compared with
9 who did not respond. 15 patients reported subjective pain
relief during the week of active treatment as compared to the
week of placebo (𝑝 < 0.05). Each patient reported an average
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Table 1: Characteristics of five included studies.
Study Year Country Method Pancreatic enzyme Duration
Halgreen et al. [6] 1986 Denmark Double-blindrandomized crossover
Enteric-coated Pancrease (lipase 20,000, amylase
20,000, and protease 25,000), two capsules at meals and
one capsule with snacks
2 weeks
Isaksson and Ihse [7] 1983 Sweden Double-blindrandomized crossover Pankreon (granulated pancreatic enzymes) One week
Malesci et al. [8] 1995 Italy Double-blindrandomized crossover
Enteric-coated Pancrex-Duo (lipase 13,000UI, amylase
43,570UI, and protease 34,375 IU) 4 months
Mossner et al. [9] 1992 Germany Double-blindrandomized crossover
Enteric-coated Panzytrat (20,000 IU; 5 × 2
capsules/day; proteases/capsule 1,000 IU) 2 weeks
O’Keefe et al. [10] 2001 South Africa Randomized, parallelgroup
Enteric-coated capsules (four capsules with meals, two
with snacks; content/capsule: lipase 10,000USP units,
protease 37,500 units, and amylase 33,200 units)
2 weeks
0
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
25 50 75 100
(%)
Low risk of bias
Unclear risk of bias
High risk of bias
Figure 2: Risk of bias graph.
of 30% pain reduction (𝑝 < 0.01). The median analgesic
consumption was not significantly different between two
groups (7.8 versus 8.9 tablets per week with enzymes versus
placebo, resp.).
In another 4-week double-blind randomized crossover
study, 20 Danish patients [11 with (Halgreen et al., (1)) and
9 without steatorrhea (Halgreen et al., (2))] with chronic
pancreatitis were included, based on a reduced exocrine
pancreatic function using Lundh test and at least one of the
pancreatic calcifications, previous acute attacks of pancreati-
tis, and/or typical abnormalities by ERCP [6]. Each patient
randomly received either enzymes or placebo for 2 weeks
followed by the other preparation for another 2 weeks. Pain
was measured based on a 10 cm linear analogue scale (0–10).
The results showed that none of the postprandial pain scores,
pain scores between meals, number of pain attacks, analgesic
consumption, subjective pain scores, or general well-being
were significantly different in two groups.
In another prospective crossover placebo-controlled
double-blind multicenter study from Germany, 47 patients
with chronic pancreatitis (based on abdominal ultrasound,
ERCP, and abdominal CT) were included to receive porcine
pancreatic extracts or placebo. After two weeks there was no
significant difference between the two groups with regard to
pain score or analgesic consumption.
Malesci et al. reported a double-blind randomized
crossover study in 26 Italian patients with chronic pancreati-
tis based on clinical presentation and the presence of ductal
changes at ERCP, pancreatic calcifications, abnormalities at
ultrasonography, and pancreatic insufficiency at the secretin-
cerulein test [8]. They were randomly assigned to 4-week
therapy with enzymes or placebo followed by 4 weeks of
alternate therapy. The pain was measured using a 10 cm
linear visual analogue scale (0–10). Four patients left or were
withdrawn from the study. In the 22 patients who ended
the trial, the 4-month cumulative score, number of days and
hours with pain, and the number of long-lasting (>12 h) pain
attacks were not statistically different in two groups. The
median analgesic consumption, adjusted for drug potency,
was also not statistically different.
A newer randomized parallel-group study from South
Africa included patients with chronic pancreatitis based on
suppressed cholecystokinin-stimulated enzyme secretion or
steatorrhea and evidence of chronic pancreatitis in CT or
ultrasound scanning, ERCP, or the presence of pancreatic
calcification on abdominal X-ray. They were included in
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Figure 3: Consensus risk of bias assessment of the included studies.
Green: low risk, yellow: unclear, and red: high risk.
a one-week placebo run-in period [10]. Among those, 29
patients who malabsorbed more than 10 g of fat per day were
randomized to receive 14 days of either enzymes or placebo.
Overall, supplementation had no significant effect on the
severity of abdominal pains or distension.
3.2. Meta-Analyses
3.2.1. Mean Daily Pain Score. Two studies reported mean
daily pain scores based on a 10 cm linear analogue scale [6, 8].
Halgreen et al. reported the results separately for thosewith or
without steatorrhea. Malesci et al. reported cumulative pain
score over the course of the study and we had to calculate
daily mean pain scores from the data in order to have
consistent information from these two studies to perform
themeta-analysis. Randommodel meta-analysis of these two
crossover studies including 42 patients showed no significant
difference in themean of daily pain score between the periods
of administering pancreatic enzyme supplementation versus
placebo (mean difference: 0.09 (1.57–1.39), 𝑝 = 0.91). There
was significant heterogeneity among studies as expected from
the sample size and methodology (𝑝 = 0.007, 𝐼2: 80%).
Figure 4 depicts the forest plot of this analysis. The results
remained unchanged in sensitivity analysis after exclusion of
each trial in turn.
3.2.2. Analgesic Consumption. Two studies reported average
weekly analgesic consumption [6, 7]. Halgreen et al. reported
the results separately for those with or without steatorrhea.
Random model meta-analysis of these two crossover studies
including 39 patients showed no significant difference in the
average weekly analgesic consumption between the periods
of administering enzymes versus placebo (mean difference:
−0.30 (−2.37–1.77), 𝑝 = 0.77). There was significant hetero-
geneity among studies as expected from the sample size and
methodology (𝑝 < 0.00001, 𝐼2: 91%). Figure 5 depicts the
forest plot of this analysis. The results remained unchanged
in sensitivity analysis after exclusion of each trial in turn.
4. Discussion
To our knowledge, this is the first comprehensive systematic
review and meta-analysis specifically done to address the
value of enzyme supplementation in relieving pain in patients
with chronic pancreatitis and reports a meta-analysis of
subjective pain scores. This systematic review and meta-
analysis provided further evidence for the lack of effectiveness
in using enzyme supplementation in themanagement of pain
in patients with chronic pancreatitis.
The only previous meta-analysis done on this topic was
done by Brown et al. in 1997 [11]. They looked at patient’s
preference in choosing enzyme supplements versus placebo.
The pooled percentage of patients per study who preferred
pancreatic enzyme to placebo was 52% ((45%–60%), 𝑝 =
0.52). They did not report any data on pain scores among
studies. However, their conclusion is consistent with what we
found in our study.
Only one small old study using non-enteric-coated pan-
creatic enzyme supplements showed improvement in pain as
compared to placebo [7]. However, it has one major method-
ological concern of possible selection bias, since 40% of the
included patients had previously undergone surgery and the
authors did not report subgroup data for those who had not
have surgery.Therefore, it would be cautious not to generalize
the results to patient with surgically intact pancreas. One
can also argue that the different results of this study might
be explained by the use of non-enteric-coated as compared
to enteric-coated form of enzyme supplementation. Enteric-
coated enzyme supplements are released in the mid-small
bowel and thereforemay not effectively suppress the feedback
loops regulating release of cholecystokinin that occurs in
duodenum [2]. This theoretical advantage of non-enteric-
coated over enteric-coated forms has not been proved in any
controlled clinical trials. Even if this was true, the result of
this small study could not be generalized to daily practice,
since pancreatic enzyme supplements prescribed in the US
are almost exclusively enteric-coated.
A Cochrane review on the role of pancreatic enzyme
supplements in chronic pancreatitis used several outcomes,
including pain and analgesic consumption [12]. They con-
cluded that enzyme supplementswere not beneficial in reduc-
ing pain or steatorrhea in patients with chronic pancreatitis.
However, the study failed to perform any meta-analysis since
the reported outcomes in their included studies were not
similar.
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Figure 4: Random model meta-analysis of the mean of daily pain score in two crossover studies (𝑛 = 42).
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Figure 5: Random model meta-analysis of the average analgesic consumption per week in two crossover studies (𝑛 = 39).
One drawback of our study relates to the nature of sys-
tematic review and meta-analysis. The possibility of missed
trials cannot be completely ruled out. We minimized this
possibility by including several types of publications and
search methods. Our study did not include any patient-level
data analysis due to insufficient reported data and therefore
is unable to characterize potential individual predictors of
response to enzyme supplementation. If such data were
available, it would help in predicting patients who may see
pain relief from the therapy.The other main limitation of our
study is the heterogeneity among the included studies. All
studies included in the meta-analysis were published more
than two decades ago and the authors did not necessarily
follow the current standards in reporting methodology and
results. This significantly contributed to the observed hetero-
geneity. Despite this, the main results of each meta-analysis
confirmed the conclusion from each individual included
study. Moreover, to minimize the effect of heterogeneity we
used random effects model rather than a fixed effects model
meta-analysis [5].
The result of this study should be interpreted with
caution given the poor quality of included studies. A large
randomized controlled trial comparing PES and identical
placebo in patients with chronic pancreatitis will be optimal
to address this question. Despite lack of evidence on effective-
ness of enzyme supplements and their significant cost, many
gastroenterologists still use them. Our findings indicate that
this practice should be discouraged.
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